|
Neonatal Intensive Care Drug Manual
|
| bet | 215/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Fluconazole
Revision Date : 13-1-2021
|
Approved : TC, KOH
|
Alert
|
The Antimicrobial Stewardship Team recommends this drug as: Restricted.
|
Indication
|
Treatment of systemic infection and meningitis caused by susceptible Candida species.
Prophylaxis from Candida infection.
|
Action
|
Triazole antifungal which selectively inhibits fungal cytochrome P-450 sterol C-14 alpha demethylation.
|
Drug type
|
Antifungal.
|
Trade name
|
IV: Aspen Fluconazole, Diflucan, Fluconazole Alphapharm, Fluconazole Claris, Fluconazole Hexal, Fluconazole Sandoz, Fluconazole Solution (Baxter). ORAL: Diflucan
|
Presentation
|
IV: 2 mg/mL injection
ORAL: 50 mg/ 5 mL powder for reconstitution
|
Dose
|
TREATMENT
Loading dose: 25 mg/kg
Maintenance dose: 12 mg/kg DAILY to start 24 hours after loading dose.
The regimen without a loading dose may take up to 5 days to reach steady state. Steady state can be reached in 2 days if a loading dose is used.
PROPHYLAXIS*
6 mg/kg TWICE per week
*Fluconazole prophylaxis may be considered in high risk infants following completion of treatment for Candida sepsis but still carrying risk of recurrence – e.g., presence of indwelling catheters and ongoing skin thrush.
|
Dose adjustment
|
No information.
|
Maximum dose
|
|
|
|
| |
